MTA1 Antibody

What is MTA1 protein and what are its key characteristics?

MTA1 (Metastasis Associated Protein 1) is a transcriptional coregulator that can function as both a transcriptional corepressor and coactivator. In humans, the canonical protein has 715 amino acid residues with a molecular mass of approximately 80.8 kDa. MTA1 is primarily localized in the nucleus and cytoplasm, with up to three different isoforms reported. The protein undergoes various post-translational modifications including ubiquitination, sumoylation, acetylation, and phosphorylation .

MTA1 is a component of the nucleosome remodeling and histone deacetylation (NURD) complex, which is essential for ATP-dependent chromatin remodeling and histone deacetylase activity. Its structural integrity, which includes an SH3-binding motif and a zinc finger domain, is crucial for protein-protein interactions critical for NURD complex assembly and activity .

What are the common applications of MTA1 antibodies in scientific research?

MTA1 antibodies are utilized in various research applications including:

• Western Blotting (WB): The most widely used application for detecting MTA1 protein expression levels

• Immunohistochemistry (IHC): For localizing MTA1 in tissue sections and evaluating expression patterns

• Immunofluorescence (IF)/Immunocytochemistry (ICC): For cellular localization studies

• Immunoprecipitation (IP): For studying protein-protein interactions involving MTA1

• Chromatin Immunoprecipitation (ChIP): For analyzing MTA1 interactions with chromatin

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of MTA1

How is MTA1 functionally involved in cancer progression?

MTA1 plays significant roles in cancer progression through multiple mechanisms:

• Transcriptional regulation: MTA1 facilitates transcriptional repression by promoting the association of repressor molecules with chromatin, influencing gene expression patterns .

• Metastasis promotion: MTA1 is overexpressed in various human cancers and its expression is associated with tumor invasion, metastasis, and poor prognosis .

• Angiogenesis regulation: In endothelial cells, MTA1 is essential for angiogenesis and may be involved in different steps of the angiogenic process compared to the VEGF/VEGFR2 pathway .

• Metabolic reprogramming: MTA1 interacts with the ATP synthase complex in mitochondria to facilitate cancer cell growth and metastasis by driving mitochondrial glucose metabolism reprogramming .

• EMT induction: MTA1 promotes epithelial-to-mesenchymal transitions and expression of angiogenic factors, enhancing cancer cell proliferation and invasion .

What strategies should be employed for optimizing MTA1 antibody specificity validation?

For rigorous MTA1 antibody validation, implement these methodological approaches:

• Control cell lines: Compare MTA1 expression in known positive cell lines (A549, HeLa, NIH/3T3, HEK-293T, MCF-7) versus MTA1-knockout cells .

• Multiple detection methods: Cross-validate findings using at least two independent techniques (e.g., WB and IHC/IF) .

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide to confirm binding specificity. For example, with antibodies generated against peptides like "PGDVFYMPKE" from the internal region of MTA1 .

• Genomic approaches: Use MTA1 knockdown (siRNA) or knockout (CRISPR-Cas9) cells as negative controls, and MTA1-overexpression systems as positive controls .

• Multiple antibody validation: Compare results using antibodies targeting different epitopes of MTA1:

  Antibody Type	Epitope Region	Applications
  Monoclonal (D17G10)	Not specified	WB, IP, ChIP
  Monoclonal (D40D1)	Not specified	WB, IHC
  Polyclonal	Internal Region (PGDVFYMPKE)	WB, ELISA, IHC
  Monoclonal (A-11)	Human-specific	WB, IP, IF, IHC, ELISA

  This multi-antibody approach enhances detection reliability .

How should researchers address contradictory MTA1 expression data in different experimental systems?

When faced with contradictory MTA1 expression data:

• Standardize detection conditions: Use consistent antibody concentrations, incubation times, and detection systems. For Western blotting, dilutions between 1:500-1:2000 are typically recommended .

• Consider protein isoforms: Account for the presence of up to three different MTA1 isoforms, which may be differentially detected by various antibodies .

• Evaluate subcellular fractionation: MTA1 localizes to both nucleus and cytoplasm, with additional mitochondrial localization recently discovered. Ensure proper cellular fractionation when analyzing compartment-specific expression .

• Assess post-translational modifications: MTA1 undergoes various modifications that may affect antibody recognition. Consider using phospho-specific or modification-specific antibodies when relevant .

• Context-dependent expression: MTA1 expression varies across tissue types and disease states. High expression in testis is normal, while elevated expression in epithelial tissues may indicate pathology .

• Quantification method standardization: Use digital image analysis for IHC with standardized scoring systems like the Immunohistochemistry Optical Density Score (IODS) to enable objective comparisons between studies .

What are the optimal conditions for studying MTA1 interactions with the ATP synthase complex?

For investigating MTA1-ATP synthase interactions:

• Co-immunoprecipitation optimization:

  • Use antibodies specific to both MTA1 and ATP5A (ATP synthase F1 subunit alpha)

  • Perform reciprocal IPs (pull down with anti-MTA1 and blot for ATP5A, then vice versa)

  • Include appropriate negative controls (IgG control, MTA1-KO cells)

• Subcellular fractionation:

  • Isolate mitochondrial fractions using differential centrifugation

  • Confirm fraction purity using organelle-specific markers

  • Compare MTA1 levels in nuclear, cytoplasmic, and mitochondrial fractions

• Functional assessment:

  • Measure ATP production in MTA1-KO versus MTA1-overexpressing cells

  • Use ATP synthase inhibitors (e.g., oligomycin A) to determine if MTA1-mediated effects are ATP synthase-dependent

  • Assess mitochondrial oxygen consumption rate (OCR) and extracellular acidification rate (ECAR)

• Protein-protein interaction visualization:

  • Use immunofluorescence to visualize co-localization of MTA1 and ATP5A in mitochondria

  • Employ proximity ligation assays to confirm direct interactions

  • Consider structured illumination microscopy for higher resolution imaging

What are the key methodological considerations for immunohistochemical detection of MTA1?

For optimal IHC detection of MTA1:

• Antigen retrieval methods:

  • Use TE buffer (pH 9.0) as the preferred method

  • Alternative: citrate buffer (pH 6.0) may be used if TE buffer results are suboptimal

• Antibody selection and dilution:

  • For paraffin-embedded tissues: Use antibodies validated for IHC-P (e.g., ab226960 at 1:500 dilution)

  • For polyclonal antibodies: Typical working dilutions range from 1:50-1:500

  • For monoclonal antibodies: Follow manufacturer recommendations (e.g., 1:50 for D40D1 XP)

• Signal detection systems:

  • DAB (3,3'-diaminobenzidine) for chromogenic detection

  • Fluorescent secondary antibodies for co-localization studies

  • Amplification systems for low-abundance detection

• Quantification methods:

  • Semi-quantitative scoring using IODS

  • Digital image analysis with appropriate software

  • Assess both intensity and percentage of positive cells

• Positive and negative tissue controls:

  • Positive controls: Human prostate cancer tissue, human skin cancer tissue

  • Negative controls: Primary antibody omission and isotype controls

  • Tissue-specific expression pattern awareness (nuclear vs. cytoplasmic staining)

How can researchers effectively analyze MTA1's role in angiogenesis through antibody-based techniques?

To investigate MTA1's role in angiogenesis:

• In vitro tube formation assays:

  • Compare tube formation between wild-type and MTA1-KO endothelial cells

  • Evaluate MTA1-overexpression MTA1-KO cells to assess functional rescue

  • Analyze both VEGF-dependent and VEGF-independent tube formation

• Protein-protein interaction analysis:

  • Study MTA1/S100A4 complex formation using co-immunoprecipitation

  • Assess phosphorylation levels of non-muscle myosin heavy chain IIa (NMIIa)

  • Investigate whether MTA1 regulates cytoskeletal dynamics in endothelial cells

• Immunofluorescence co-localization:

  • Visualize MTA1 expression in endothelial cells during different stages of tube formation

  • Co-stain with endothelial markers (CD31, VE-cadherin) and angiogenic factors

  • Use confocal microscopy for detailed subcellular localization analysis

• In vivo angiogenesis models:

  • Employ MTA1 antibodies for immunohistochemical analysis of tumor vasculature

  • Compare vessel density and morphology in MTA1-high versus MTA1-low regions

  • Use matrigel plug assays to assess angiogenic potential in vivo

What approaches can be used to investigate MTA1's interactions within the NURD complex?

For studying MTA1 within the NURD complex:

• Sequential co-immunoprecipitation:

  • Initial IP with MTA1 antibody followed by secondary IP with antibodies against other NURD components

  • Use specific antibodies to HDAC1/2, Mi-2α/β, MBD3, and RBBP4/7

  • Include appropriate controls for each precipitation step

• ChIP-sequencing approaches:

  • Perform ChIP with MTA1 antibodies suitable for ChIP applications (e.g., D17G10)

  • Compare MTA1 binding sites with those of other NURD components

  • Analyze histone modification patterns at MTA1-bound regions

• Proximity-dependent biotinylation:

  • Fuse MTA1 to a biotin ligase (BioID or TurboID)

  • Identify proximal proteins through streptavidin pulldown and mass spectrometry

  • Validate interactions using traditional co-IP with MTA1 antibodies

• Functional assays:

  • Measure histone deacetylase activity in MTA1 immunoprecipitates

  • Compare chromatin remodeling activity in wild-type versus MTA1-depleted cells

  • Assess transcriptional repression at known NURD target genes

What are common challenges in MTA1 Western blotting and their solutions?

How can researchers study the dual nuclear and cytoplasmic functions of MTA1?

To investigate MTA1's compartment-specific functions:

• Subcellular fractionation protocols:

  • Perform differential centrifugation to separate nuclear, cytoplasmic, and mitochondrial fractions

  • Verify fraction purity using compartment-specific markers (HDAC1 for nucleus, GAPDH for cytoplasm, COX IV for mitochondria)

  • Quantify MTA1 distribution across fractions by Western blotting

• Compartment-targeted MTA1 variants:

  • Create nuclear localization signal (NLS) or nuclear export signal (NES) tagged MTA1 constructs

  • Generate mitochondrial targeting sequence (MTS) tagged MTA1 for mitochondrial targeting

  • Validate localization using immunofluorescence with MTA1 antibodies

• Co-localization studies:

  • Perform immunofluorescence using MTA1 antibodies alongside markers for different subcellular compartments

  • Use super-resolution microscopy for detailed localization analysis

  • Quantify co-localization using appropriate software and statistical analysis

• Functional assays:

  • Nuclear function: ChIP assays to study chromatin interactions

  • Cytoplasmic function: Co-IP to identify cytoplasmic binding partners

  • Mitochondrial function: ATP production and respiration measurements

What strategies can optimize MTA1 detection in patient-derived cancer samples?

For effective MTA1 detection in clinical samples:

• Sample preparation optimization:

  • For FFPE tissues: Determine optimal fixation times and antigen retrieval methods

  • For frozen tissues: Standardize freezing protocols and section thickness

  • For liquid biopsies: Develop sensitive detection methods for circulating tumor cells

• Multi-antibody approach:

  • Use antibodies recognizing different epitopes to confirm expression patterns

  • Include both monoclonal and polyclonal antibodies in optimization panels

  • Consider species cross-reactivity when using xenograft models

• Quantification standardization:

  • Develop objective scoring systems based on staining intensity and positive cell percentage

  • Use digital pathology approaches for reproducible quantification

  • Include internal reference standards for batch normalization

• Correlation with clinical outcomes:

  • Stratify patients based on MTA1 expression levels (high vs. low)

  • Perform Kaplan-Meier analysis to determine prognostic value

  • Conduct multivariate analyses to assess independent prognostic role

• Response to therapy assessment:

  • Monitor MTA1 expression before and after treatment

  • Correlate changes in expression with therapeutic outcomes

  • Investigate potential use as a predictive biomarker

How can MTA1 antibodies be utilized to study its role in inflammatory conditions?

Recent research has revealed MTA1's role in inflammatory diseases like colitis:

• Inflammation model systems:

  • Detect MTA1 expression in experimental colitis using immunohistochemistry

  • Compare expression in inflamed versus normal tissues

  • Correlate MTA1 levels with inflammatory markers (IL-1β, TNF-α)

• Mechanistic investigations:

  • Study MTA1's interaction with HIF1A and subsequent regulation of AQP4

  • Assess effects of MTA1 silencing on inflammatory cytokine production

  • Investigate MTA1's role in epithelial cell apoptosis during inflammation

• Therapeutic targeting assessment:

  • Use MTA1 antibodies to monitor expression changes following treatment

  • Correlate reduced MTA1 expression with disease improvement

  • Investigate combined targeting of MTA1-mediated pathways

• Translational applications:

  • Develop standardized IHC protocols for inflammatory bowel disease biopsies

  • Assess MTA1 as a potential biomarker for disease severity or progression

  • Investigate correlation between MTA1 levels and response to anti-inflammatory therapies

What novel approaches can advance our understanding of MTA1's metabolic functions?

To investigate MTA1's emerging role in cellular metabolism:

• Mitochondrial function analysis:

  • Study MTA1-ATP synthase interactions using co-immunoprecipitation and proximity ligation assays

  • Measure ATP production in MTA1-manipulated cells

  • Assess oxygen consumption and extracellular acidification rates

• Metabolic profiling:

  • Perform metabolomics analysis in MTA1-knockout versus wild-type cells

  • Focus on glucose metabolism intermediates

  • Investigate lipid metabolism alterations

• Drug sensitivity testing:

  • Screen anticancer drug libraries for compounds affecting the MTA1-ATP5A axis

  • Correlate MTA1 expression with drug response profiles

  • Investigate combination strategies targeting both MTA1 and metabolic pathways

• In vivo metabolic studies:

  • Use PET imaging with metabolic tracers in MTA1-high versus MTA1-low tumors

  • Assess glycolytic versus oxidative metabolism based on MTA1 status

  • Investigate whether metabolic interventions can overcome MTA1-mediated effects